Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation
Use Could Be Restricted To Most Severe Patients
CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.
